respiratory disease
Conditions
Interventions
study group:ciprofol iv
control group:propofol iv
Sponsors
Huadong Hospital Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
65 Years to 100 Years
Inclusion criteria
Inclusion criteria: (1) Age greater than 60 years old; (2) American Society of Anesthesiologists (ASA) classification I-III; (3) Elderly patients undergoing elective daytime prostate biopsy under intravenous anesthesia; (4) Body mass index (BMI) =18 and =30 kg/m2; (5) Vital signs: respiratory rate =10 and =24 breaths/min; oxygen saturation (SpO2) =95% while breathing room air; (6) Able to understand the study process and methods, and voluntarily participate in the study.
Exclusion criteria
Exclusion criteria: (1) Patients with contraindications to general anesthesia or a history of anesthesia accidents; (2) Patients known or suspected to be allergic or contraindicated to propofol injection, etomidate injection excipients, benzodiazepine drugs, opioid drugs, muscle relaxants, etc.; (3) Patients with acute upper respiratory tract infections, asthma attacks, or acute severe laryngeal diseases; (4) Patients with a history of gastrointestinal diseases such as gastrointestinal retention, active bleeding, and conditions that may cause reflux aspiration; (5) Patients with concurrent cerebral injury, intracranial hypertension, history of stroke or cerebrovascular accidents; (6) Patients with respiratory failure, obstructive pulmonary disease, difficult airways, or judged to have difficult tracheal intubation (modified Mallampati score III or IV); (7) Uncontrolled hypertension, hypotension, and diabetes; (8) Patients with severe arrhythmias, heart failure, unstable angina, myocardial infarction, etc.; (9) Patients with severe liver dysfunction or severe renal dysfunction; (10) Patients with a history of alcohol abuse or drug dependence; (11) Patients who abuse or have long-term use of anesthetic, sedative, or analgesic drugs; (12) Patients with a history of mental illness; (13) Patients who have participated in any drug clinical trials within one month before screening; (14) Subjects that the researcher believes have any other factors that are not suitable for participating in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Respiratory related adverse reactions composite endpoints ( including respiratory depression, apnea, SPO2 < 93 % ); | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of successful induction of anesthesia; | — |
Countries
China
Contacts
Public ContactLiu Songbin
Huadong Hospital Hospital Affiliated to Fudan University
Outcome results
None listed